scholarly journals Chelerythrine chloride from Macleaya cordata induces growth inhibition and apoptosis in human gastric cancer BGC-823 cells

2012 ◽  
Vol 2 (5) ◽  
pp. 464-471 ◽  
Author(s):  
Zhengfu Zhang ◽  
Ying Guo ◽  
Lingwei Zhang ◽  
Jianbin Zhang ◽  
Xionghui Wei
Keyword(s):  
Gastric Cancer ◽  
Growth Inhibition ◽  
Human Gastric Cancer ◽  
Chelerythrine Chloride ◽  
Macleaya Cordata

scholarly journals Annonaceous acetogenins mediated up-regulation of Notch2 exerts growth inhibition in human gastric cancer cells in vitro

Oncotarget ◽  
2017 ◽  
Vol 8 (13) ◽  
pp. 21140-21152 ◽  
Author(s):  
Yan Li ◽  
Jianbin Ye ◽  
Zhongbiao Chen ◽  
Junjie Wen ◽  
Fei Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Inhibition ◽  
Cancer Cells ◽  
Human Gastric Cancer ◽  
Gastric Cancer Cells ◽  
Annonaceous Acetogenins

Recombinant human leptin induces growth inhibition and apoptosis in human gastric cancer MGC-803 cells

2012 ◽  
Vol 13 (4) ◽  
pp. 305-314 ◽  
Author(s):  
Na Wu ◽  
Yongjun Wang ◽  
Shengyu Wang ◽  
Yuqiang Chen ◽  
Jianghua Yan
Keyword(s):  
Gastric Cancer ◽  
Growth Inhibition ◽  
Human Gastric Cancer

scholarly journals Growth inhibition and induction of apoptosis in SGC-7901 human gastric cancer cells by evodiamine

2014 ◽  
Vol 9 (4) ◽  
pp. 1147-1152 ◽  
Author(s):  
LI YANG ◽  
XIN LIU ◽  
DAN WU ◽  
MAN ZHANG ◽  
GUIPING RAN ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Growth Inhibition ◽  
Cancer Cells ◽  
Human Gastric Cancer ◽  
Gastric Cancer Cells ◽  
Induction Of Apoptosis

Antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 33-33 ◽  
Author(s):  
Changhua Zhang ◽  
Katherine T Ostapoff ◽  
Niranjan Awasthi ◽  
Margaret A. Schwarz ◽  
Roderich Schwarz
Keyword(s):  
Gastric Cancer ◽  
Cell Proliferation ◽  
Antitumor Activity ◽  
Tumor Growth ◽  
Growth Inhibition ◽  
Tumor Growth Inhibition ◽  
Human Gastric Cancer ◽  
Targeting Therapy ◽  
Paclitaxel Treatment

33 Background: Gastric cancer is the second most common cause of cancer related death worldwide and lacks highly effective adjuvant or definitive systemic treatment for advanced disease. Nab-paclitaxel is a novel microtubule-targeting cytotoxic agent and not tested in gastric cancer as of yet. Methods: Human gastric cancer cell lines AGS, NCI-N87 and SNU16 were studied for treatment effects on cell proliferation, mitotic arrests and apoptosis in vitro and vivo. Tumor growth and survival studies were performed in murine xenografts. Results: Nab-paclitaxel inhibited cell proliferation with an IC50 of 2.01 nM in SNU16, 23.3 nM in AGS and 48.69 nM in NCI-N87 cells after 72-hour treatment, which was lower than that of oxaliplatin (1.05 μM to 1.51μM) and epirubicin (0.12 μM to 0.25 μM). Nab-paclitaxel treatment caused increased expression of the mitotic-spindle associated phospho-stathmin, nuclear fragmentation or karyopyknosis, and apoptotic events as confirmed through increased expression of cleaved-PARP and caspase-3. After a two-week nab-paclitaxel, oxaliplatin or epirubicin treatment, the local tumor growth inhibition rate was 77, 17.2 and 21.4 percent, respectively (p=0.002). Effects of therapy on tumoral proliferative and apoptotic indices corresponded with tumor growth inhibition data, while expression of phospho-stathmin also increased in tissues. There was an increase in median animal survival after nab-paclitaxel treatment (86 days) compared to controls (24 days, p=0.0004) or to oxaliplatin therapy (37.5 days, p=0.0005). Conclusions: The strong antitumor activity of nab-paclitaxel in experimental gastric cancer supports such microtubule-targeting therapy for clinical application. Nab-paclitaxel benefits were observed independent from phosphorylated stathmin expression at baseline, putting into question the consideration of nab-paclitaxel use in gastric cancer based on this putative biomarker.

Sign in / Sign up

Export Citation Format

Share Document